Advertisement

Clinical Journal of Gastroenterology

, Volume 12, Issue 1, pp 63–70 | Cite as

Three renal failure cases successfully treated with ombitasvir/paritaprevir/ritonavir for genotype 1b hepatitis C virus reinfection after liver transplantation

  • Noriaki Orita
  • Tetsuro ShimakamiEmail author
  • Hajime Sunagozaka
  • Rika Horii
  • Kouki Nio
  • Tekeshi Terashima
  • Noriho Iida
  • Masaaki Kitahara
  • Hajime Takatori
  • Kazunori Kawaguchi
  • Kazuya Kitamura
  • Kuniaki Arai
  • Taro Yamashita
  • Yoshio Sakai
  • Tatsuya Yamashita
  • Eishiro Mizukoshi
  • Masao Honda
  • Shuichi Kaneko
Case Report

Abstract

We report three cases of genotype 1b hepatitis C virus (HCV) reinfection after liver transplantation. When antiviral treatment was considered, all three patients had renal dysfunction and had been treated with immunosuppressive agents for a long time; one with tacrolimus (TAC) and the others with cyclosporine A (CyA). Therefore, the possible antiviral regimens among direct-acting antivirals (DAA) were limited and so we treated all three patients with ombitasvir/paritaprevir/ritonavir (OBV/PTV/r). Because ritonavir is known to markedly increase the blood concentration of TAC and CyA through drug–drug interactions, close monitoring of blood concentrations of TAC or CyA and dose adjustments of immunosuppressive agents were needed. Sustained virus response was achieved in all the patients treated, and there were no adverse effects or transplant rejection. OBV/PTV/r might be a useful DAA regimen for patients with genotype 1 HCV reinfection in the setting of renal dysfunction.

Keywords

Ombitasvir/paritaprevir/ritonavir Hepatitis C virus Liver transplantation Reinfection Direct-acting antiviral 

Notes

Acknowledgements

This work was partially supported by the following grants: Grant-in-Aid for Scientific Research (KAKENHI) (C), (to Te.S., Grant ID 15K08492). We thank Mr. Steve Burke for his critical reading of the manuscript.

References

  1. 1.
    Akamatsu N, Sugawara Y, Kokudo N, et al. Outcomes of living donor liver transplantation for hepatitis C virus-positive recipients in Japan: results of a nationwide survey. Transpl Int. 2014;27:767–74.CrossRefGoogle Scholar
  2. 2.
    Firpi RJ, Abdelmalek MF, Soldevila-Pico C, et al. One-year protocol liver biopsy can stratify fibrosis progression in liver transplant recipients with recurrent hepatitis C infection. Liver Transpl. 2004;10:1240–47.CrossRefGoogle Scholar
  3. 3.
    Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet. 1997;349:825–32.CrossRefGoogle Scholar
  4. 4.
    Berenguer M. Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. J Hepatol. 2008;49:274–87.CrossRefGoogle Scholar
  5. 5.
    Tanaka T, Sugawara Y, Akamatsu N, et al. Use of simeprevir following pre-emptive pegylated interferon/ribavirin treatment for recurrent hepatitis C in living donor liver transplant recipients: a 12-week pilot study. J Hepatobiliary Pancreat Sci. 2015;22:144–50.CrossRefGoogle Scholar
  6. 6.
    Ikegami T, Yoshizumi T, Kato M, et al. Reduced-dose telaprevir-based triple antiviral therapy for recurrent hepatitis C after living donor liver transplantation. Transplantation. 2014;98:994–9.CrossRefGoogle Scholar
  7. 7.
    Kumada H, Suzuki Y, Ikeda K, et al. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology. 2014;59:2083–91.CrossRefGoogle Scholar
  8. 8.
    Levitsky J, Fiel MI, Norvell JP, et al. Risk for immune-mediated graft dysfunction in liver transplant recipients with recurrent HCV infection treated with pegylated interferon. Gastroenterology. 2012;142:1132–9.e1.CrossRefGoogle Scholar
  9. 9.
    Charlton M, Gane E, Manns MP, et al. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. Gastroenterology. 2015;148:108–17.CrossRefGoogle Scholar
  10. 10.
    Kawaoka T, Imamura M, Morio K, et al. Three patients treated with daclatasvir and asunaprevir for recurrent hepatitis C after liver transplantation: case report. Hepatol Res. 2016;46:707–12.CrossRefGoogle Scholar
  11. 11.
    Yu ML, Chen YL, Huang CF, et al. Paritaprevir/ritonavir/ombitasvir plus dasabuvir with ribavirin for treatment of recurrent chronic hepatitis C genotype 1 infection after liver transplantation: real-world experience. J Formos Med Assoc. 2017.  https://doi.org/10.1016/j.jfma.2017.06.006 (Epub ahead of print).Google Scholar
  12. 12.
    Kwo PY, Mantry PS, Corakley E, et al. An interferon-free antiviral regimen for HCV after liver transplantation. N Engl J Med. 2014;371:2375–82.CrossRefGoogle Scholar
  13. 13.
    Righi E, Londero A, Carnelutti A, et al. Impact of new treatment options for hepatitis C virus infection in liver transplantation. World J Gastroenterol. 2015;21:10760–75.CrossRefGoogle Scholar
  14. 14.
    Kawaoka T, Imamura M, Morio K, et al. Three patients treated with sofosbuvir plus ledipasvir for recurrent hepatitis C after liver transplantation. Clin J Gastroenterol. 2017;10:179–84.CrossRefGoogle Scholar
  15. 15.
    Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014;370:1889–98.CrossRefGoogle Scholar
  16. 16.
    Kumada H, Chayama K, Rodrigues L Jr, et al. Randomized phase 3 trial of ombitasvir/paritaprevir/ritonavir for hepatitis C virus genotype 1b-infected Japanese patients with or without cirrhosis. Hepatology. 2015;62:1037–46.CrossRefGoogle Scholar
  17. 17.
    Drafting Committee for Hepatitis Management Guidelines, the Japan Society of Hepatology. JSH guidelines for the management of hepatitis C virus infection: a 2014 update for Genotype 1. Hepatol Res. 2014;44:59–70.CrossRefGoogle Scholar
  18. 18.
    European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2016. Hepatology. 2017;66:153–94.CrossRefGoogle Scholar
  19. 19.
    AASLD/IDSA HCV Guidance Panel. Hepatitis C guideline: AASLD and IDSA guidelines. Recommendations for testing, managing, and treating hepatitis C. Hepatology. 2015;62:932–54.CrossRefGoogle Scholar
  20. 20.
    Suda G, Furusyo N, Toyoda H, et al. Daclatasvir and asunaprevir in hemodialysis patients with hepatitis C virus infection: a nationwide retrospective study in Japan. J Gastroenterol. 2018;53:119–28.  https://doi.org/10.1007/s00535-017-1353-y (Epub 2017 May 30).CrossRefGoogle Scholar
  21. 21.
    Atsukawa M, Tsubota A, Koushima Y, et al. Efficacy and safety of ombitasvir/paritaprevir/ ritonavir in dialysis patients with genotype 1b chronic hepatitis C. Hepatol Res. 2017;47:1429–37.CrossRefGoogle Scholar
  22. 22.
    Badri P, Dutta S, Coakley E, et al. Pharmacokinetics and dose recommendations for cyclosporine and tacrolimus when coadministered with ABT-450, ombitasvir, and dasabuvir. Am J Transplant. 2015;15:1313–22.CrossRefGoogle Scholar
  23. 23.
    VIEKIRA PAK Highlights of Prescribing Information FDA. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206619lbl.pdf. Accessed 29 Mar 2018.
  24. 24.
    Lucey MR, Terrault N, Ojo L, et al. Long-term management of the successful adult liver transplant: 2012 Practice Guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Liver Transplant. 2013;19:3–26.CrossRefGoogle Scholar
  25. 25.
    GLE/PIB Highlights of Prescribing Information. FDA. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209394s000lbl.pdf. Accessed 29 Mar 2018.
  26. 26.
    EBV plus GZR Highlights of Prescribing Information. FDA. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208261s002lbl.pdf. Accessed 29 Mar 2018.

Copyright information

© Japanese Society of Gastroenterology 2018

Authors and Affiliations

  • Noriaki Orita
    • 1
  • Tetsuro Shimakami
    • 1
    Email author
  • Hajime Sunagozaka
    • 1
  • Rika Horii
    • 1
  • Kouki Nio
    • 1
  • Tekeshi Terashima
    • 1
  • Noriho Iida
    • 1
  • Masaaki Kitahara
    • 1
  • Hajime Takatori
    • 1
  • Kazunori Kawaguchi
    • 1
  • Kazuya Kitamura
    • 1
  • Kuniaki Arai
    • 1
  • Taro Yamashita
    • 1
  • Yoshio Sakai
    • 1
  • Tatsuya Yamashita
    • 1
  • Eishiro Mizukoshi
    • 1
  • Masao Honda
    • 1
  • Shuichi Kaneko
    • 1
  1. 1.Department of Gastroenterology, Kanazawa University HospitalKanazawa University Graduate School of Medical ScienceKanazawaJapan

Personalised recommendations